Author

Santiago B. Ferrer

GlaxoSmithKline (Spain)ORCID 0000-0002-6672-551XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Alfonso Mendoza-LosanaiD· 2 shared Ángel Santos-Villarejo· 1 shared Charles J. ThompsoniD· 1 shared David Barros-AguirreiD· 1 shared Esther Pérez‐HerrániD· 1 shared Esther Porras de FranciscoiD· 1 shared Helena I. BoshoffiD· 1 shared Joaquín Rullás· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Alfonso Mendoza-LosanaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintJun 16, 2025

Exploring Mycobacterium tuberculosis rRNA Transcriptomic Signatures asResponse to Anti-TB Treatment in Whole Blood RNA-seq Data

Patricio Lopez-Exposito, Juan Calvet-Seral, Santiago B. Ferrer…·Juan José Vaquero

The paper analyzes whole-blood RNA-seq data from TB patients to identify rRNA transcriptomic signatures that change during anti-TB treatment, suggesting potential biomarkers for monitoring treatment response.

DOI 10.1101/2025.06.16.659901

humanbulk RNA-seq

𝕏 PostBluesky

MicrobiologyDrug Resistance UpdatesPeer-reviewedFeb 15, 2025

Sanfetrinem, an oral beta-lactam antibiotic repurposed for the treatment of tuberculosis

Santiago Ramón‐García, Rubén González del Río, María Pilar Arenaz-Callao…·Robert H. Bates

This paper identifies sanfetrinem cilexetil as a promising oral beta-lactam antibiotic for tuberculosis treatment through preclinical studies showing its activity against Mtb and potential for repurposing.

10 citationstop 3%

humanexperimental assay

𝕏 PostBluesky